Perrigo reported third-quarter net sales of $989 million, a 5.2% decline year-over-year, with Core organic sales down 1.1%. Adjusted diluted EPS for the period was $0.60 on an All-In basis and $0.61 on a Core basis, compared to $0.80 and $0.67 respectively in the prior year. The company announced it has agreed to divest its Infant Formula business for up to $175 million, consisting of $40 million upfront and contingent milestones. This transaction is expected to result in an impairment loss between $275 million and $375 million in Q4 2026. Perrigo also updated its full-year adjusted EPS outlook to $2.15-$2.35 on a Core basis, reflecting the divestiture and softer European demand. The company operates as a leading provider of consumer self-care products and over-the-counter health solutions.
